Adding metabolic agents to prostate cancer therapy: Every rose has its thorn
Menée à partir de données portant sur des patients atteints d'un cancer métastatique de la prostate résistant à la castration et inclus dans deux essais cliniques, cette étude évalue l'efficacité, du point de vue de la survie globale et du taux de PSA, de l'ajout de metformine ou de statines à un traitement combinant acétate d'abiratérone et prednisone ou prednisolone
In constant efforts to improve the outcomes of patients with cancer, scientists frequentlyinvestigate old and commonly prescribed drugs for their potential antineoplastic features.For statins and metformin, two metabolic agents which are both often prescribed, theseantitumour properties have been suggested in preclinical studies. Recent phase 3 trials of androgen receptor signalling inhibitors may provide theopportunity to investigate these putative effects in patients with prostate cancer.In this issue of the European Journal of Cancer, two complementary retrospective studies report outcomes of the use of statins andmetformin in patients treated in clinical trials with abiraterone acetate plus prednisone/prednisolone orplacebo, and enzalutamide or placebo, respectively.
European Journal of Cancer , éditorial, 2021